Strengthen Real-World Decisions with Real-World Data

A growing body of evidence shows Integra Connect solutions can drive success with value-based, precision specialty care

Check out our latest researchExplore our data library
  • 3.5+ million

    unique patients lives available for commercial utility

  • 60+

    scientific publications over the last two years

  • 65+

    engagements with top pharma, medtech and biotech companies

  • 5000+

    provider relationships, with the largest footprint of oncology providers focused on value-based care

  • 5

    most prevalent cancers in our dataset include: breast, colorectal, leukemia, lung and prostate cancers

Go in-depth with our latest research findings

Integra Connect supports life sciences companies’ research, market access and commercial decisions with insights from one of the industry’s most complete and extensive data sets. Meet the experts spearheading our real-world evidence efforts and the insights gathered. 

WATCH: Real-world Observations Show Beneficial Outcomes in Patients with NSCLC Treated with Pembrolizumab for More than 2 Years

Research from NCCN 2023

Download the Poster

Publications & Research


Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy


Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy


Quality Initiative

Understanding testing for and treatment of homologous recombination repair (HRR)-mutated metastatic castrate-resistant prostate cancer (mCRPC): A quality initiative by Integra Connect (IC) PrecisionQ.


Quality Initiative

Management and treatment of patients (pts) with stage III unresected non-small cell lung cancer (NSCLC) at UPMC: A quality initiative by Integra Connect PrecisionQ.


The impact on hospice quality after initiation of an internal palliative care program by a community oncology practice.


The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM).


PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer.


Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.


Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US).

Interested in learning more about the findings from Integra Connect Databases?

Schedule time with our experts.
Or meet with us at one of our upcoming events.

Stay up-to-date on RWD, RWE and HEOR trends with Integra Connect